Jci_page_head_homepage_01 Jci_page_head_homepage_02
Antonia Follenzi, Daniel Benten, Phyllis Novikoff, Louisa Faulkner, Sanj Raut, Sanjeev Gupta
Published in Volume 118, Issue 3
J Clin Invest. 2008; 118(3):935–945 doi:10.1172/JCI32748
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 5
Perturbations induced by MCT in native LSECs.

Analysis of liver from MCT-pretreated FVB/N recipient mice after transplantation of LSECs from FVB/N-Tie2–GFP donor mice that had also been treated with MCT 2 weeks before cells were isolated for transplantation. (A) Tissue sections were immunostained with GFP (green) and F4/80 (red) antibodies 1 week after cell transplantation. (B) Higher magnification view of GFP and CD31 staining in a section from mouse 1 week after cell transplantation. Arrows indicate GFP-positive transplanted LSECs displaying CD31. (C) Immunostaining to identify transplanted LSECs with GFP (green) along with CD31 endothelial marker (red) 1 month after cell transplantation. (D) FACS analysis of MCT-treated FVB/N-Tie2–GFP transplanted LSECs recovered 1 week and 1 month after transplantation. The identities of CD31+/GFP LSECs for typical endothelial markers, endoglin and Flk-1, and the myeloid marker CD11b are shown in the last 6 plots of LSECs isolated from mice 1 week after cell transplantation. Nuclei stained with DAPI (blue). Original magnification, ×200 (A, C); ×630 (B). Scale bar: 10 μm (B).